{
  "abstract": "Globally, liver disease accounts for more than 2 million deaths and is the 11th leading cause of death annually. 1 Currently, there is a rise in non-communicable diseases (NCDs) of the liver, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), both of which are prominent aetiologies of cirrhosis. Despite the substantial disease burden, limited research funding in lower-income regions continues to hinder progress in liver disease prevention, treatment, and policy reform.",
  "authors": [
    {
      "affiliations": [
        "Department of Medicine, University of Washington, Seattle, Washington, USA"
      ],
      "name": "Daniel J Huynh"
    },
    {
      "affiliations": [
        "Department of Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA"
      ],
      "name": "Matthew Obusan"
    },
    {
      "affiliations": [
        "Department of Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA"
      ],
      "name": "Jinny Lu"
    },
    {
      "affiliations": [
        "Faculty of Medicine, Alexandria University, Alexandria, Egypt",
        "Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA"
      ],
      "name": "Omar Albhaisi"
    },
    {
      "affiliations": [
        "Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA",
        "Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA"
      ],
      "name": "Somaya Albhaisi"
    }
  ],
  "title": "Advancing global equity in liver disease research funding: the case of metabolic dysfunction-associated and alcohol-associated liver disease",
  "uid": "60599249-529a-5ea7-8416-ff5dc7224330"
}